Saturday 17 October 2026
Export TBIO’s income statement to Excel — free account
Telesis Bio Inc.
TBIO Healthcare Medical Devices
Revenue growth for five consecutive years, operating cash flow growth for three.
0.04
0.00
0.00%
Follow TBIO
| Older periods | Dec '23 | Mar '24 | Jun '24 | Sep '24 | |
|---|---|---|---|---|---|
Piotroski F-Score |
+8 more TTM periods Free account |
4 | 4 | 2 | 1 |
| (209.49%) | (332.08%) | (1,405.45%) | 1,013.88% | ||
| (64.60%) | (61.81%) | (62.02%) | (73.87%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(172.23%) | (199.13%) | (449.42%) | (858.27%) | |
Average Days of Receivables |
71.78 | 44.41 | 25.39 | 27.67 | |
Free Cash Flow per Share |
(22.07) | (17.20) | (13.17) | (13.45) | |
Free Cash Flow |
(36.63) | (28.73) | (22.78) | (23.85) | |
Capital Expenditures |
(1.96) | (2.00) | (0.99) | (0.98) | |
| Other line items | |||||
Cash ROIC |
(146.60%) | (224.34%) | 470.62% | 145.61% | |
Accounts Receivable Turnover |
4.89 | 5.58 | 4.01 | 5.03 | |
Accounts Payable Turnover |
4.74 | 4.49 | 6.78 | 4.65 | |
Inventory Turnover |
3.57 | 3.27 | 3.86 | 3.37 | |
Average Days of Payables |
109.41 | 71.33 | 55.74 | 60.20 | |
Days of Inventory on Hand |
128.25 | 137.38 | 49.24 | 44.31 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
63.60% | 62.11% | 72.21% | 76.25% | |
Selling, General and Administrative Expense of Revenue |
125.79% | 131.06% | 161.66% | 158.58% | |
Share Based Compensation of Revenue |
14.41% | 14.50% | 17.76% | 16.92% | |
Interest Coverage |
(14.99) | (16.43) | (21.98) | (38.00) | |
Operating CF/Net income |
0.71 | 0.57 | 0.42 | 0.48 | |
Depreciation/Fixed assets |
2.58 | 2.43 | 3.77 | 3.91 | |
Capex/Depreciation |
(0.12) | (0.12) | (0.06) | (0.06) | |
Revenue per Share |
16.57 | 14.74 | 11.09 | 9.39 | |
Operating CF per Share |
(20.89) | (16.00) | (12.59) | (12.90) | |
Capex per Share |
(1.18) | (1.19) | (0.58) | (0.55) | |
Capex to Sales |
0.07 | 0.08 | 0.05 | 0.06 |
Columns are period end dates